Indiana University Philanthropic Venture Fund has made its tenth investment, putting $200,000 into Confluence Pharmaceuticals.
Confluence Pharmaceuticals, a US-based developer of therapies for fragile X syndrome and autism spectrum disorder, has received $200,000 from the Indiana University Philanthropic Venture Fund.
The fund is operated by Indiana University Research and Technology Corp (IURTC), the fund management firm of Indiana University, and invests in university-affiliated companies.
Confluence Pharmaceuticals is working on therapies for core social and communication impairments related to fragile X syndrome and autism spectrum disorder.
Its lead candidate is aimed at people…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
